Mr. Miguel Martin reports

AURORA AND MEDRELEAF AUSTRALIA LAUNCH INDIMED TEMPO 26, FURTHER STRENGTHENING PRODUCT OFFERINGS FOR MEDICAL CANNABIS PATIENTS

Aurora Cannabis Inc. and MedReleaf Australia have launched IndiMed Tempo 26, a range of new higher-THC (tetrahydrocannabinol) dried cannabis products for qualified patients under the MedReleaf Concession Scheme (MCS). Tempo 26 will add to the portfolio of products available, giving doctors the ability to prescribe from a wider range of options for medical cannabis patients.

"We are proud to further expand the variety of high-quality medical cannabis products that Australian patients can access through the MedReleaf Concession Scheme, and with the addition of Tempo 26, doctors and patients now have more control and choice about their medical cannabis treatment than ever before," says Miguel Martin, chief executive officer of Aurora Cannabis. "We are strongly committed to our patient-first approach to cannabis and ensuring access to medical patients, in Australia, and around the world."

The MCS was developed by MedReleaf Australia and Aurora to provide high-quality products and enhance patient access to medical cannabis, which is not covered by the Pharmaceutical Benefits Scheme (PBS). Through the MCS, patients can access compassionate pricing, specifically for those with pensioner concession cards, commonwealth seniors health cards, health care cards and veterans cards (DVA).

"Through the investment of Aurora and MedReleaf Australia, we have been able to provide heavily discounted products via our MedReleaf concession scheme, which widens the choice for prescriptions and significantly improves access for disadvantaged Australian patients struggling with debilitating health conditions," says Russell Harding, MedReleaf CEO. "These products are cultivated and manufactured in Aurora's GMP accredited facilities and are made available for doctors to prescribe via the TGA's Special Access Scheme."

Aurora currently holds a 10-per-cent ownership stake in MedReleaf Australia, a fully licensed, private company. Together, they provide Australian patients with several innovative, Aurora-branded products, including dried flower, oils, soft gels and resin cartridges.

About Aurora Cannabis Inc.

Aurora is opening the world to cannabis, serving both the medical and consumer markets. Headquartered in Edmonton, Alta., Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as cannabidiol brands Reliva and KG7. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, performance, wellness and adult recreational markets wherever they are launched.

We seek Safe Harbor.